1. Home
  2. PFLT vs ABCL Comparison

PFLT vs ABCL Comparison

Compare PFLT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Floating Rate Capital Ltd.

PFLT

PennantPark Floating Rate Capital Ltd.

HOLD

Current Price

$9.26

Market Cap

899.9M

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.47

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFLT
ABCL
Founded
2010
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
899.9M
1.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PFLT
ABCL
Price
$9.26
$3.47
Analyst Decision
Buy
Buy
Analyst Count
6
5
Target Price
$10.75
$7.75
AVG Volume (30 Days)
880.3K
3.0M
Earning Date
02-09-2026
11-06-2025
Dividend Yield
13.50%
N/A
EPS Growth
N/A
N/A
EPS
0.72
N/A
Revenue
$261,427,000.00
$35,325,000.00
Revenue This Year
$11.66
$25.45
Revenue Next Year
N/A
$10.07
P/E Ratio
$12.70
N/A
Revenue Growth
40.28
7.17
52 Week Low
$8.40
$1.89
52 Week High
$11.50
$6.52

Technical Indicators

Market Signals
Indicator
PFLT
ABCL
Relative Strength Index (RSI) 53.48 40.39
Support Level $9.01 $3.32
Resistance Level $9.14 $3.82
Average True Range (ATR) 0.15 0.18
MACD -0.02 0.03
Stochastic Oscillator 42.28 27.78

Price Performance

Historical Comparison
PFLT
ABCL

About PFLT PennantPark Floating Rate Capital Ltd.

PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: